Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06844383 · ClinicalTrials.gov registry record · Phase 2
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
A Phase 2 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer), sponsored by Prostate Cancer Clinical Trials Consortium.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 126
- Enrollment target
- 2
- Study locations
NCT06844383: Recruiting Phase 2 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer), sponsored by Prostate Cancer Clinical Trials Consortium.
NCT06844383 is a Phase 2 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer) that is actively recruiting participants, run by Prostate Cancer Clinical Trials Consortium. The registered enrollment target is 126 participants, roughly in line with the 121-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06844383, a Phase 2 study of Prostate Cancer (Adenocarcinoma) and mCRPC (Metastatic Castration-resistant Prostate Cancer), is actively recruiting participants, sponsored by Prostate Cancer Clinical Trials Consortium.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 126 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate.
Conditions Studied
Interventions
- DRUG Talazoparib
- DRUG Talazoparib with enzalutamide
Study Locations (2)
Massachusetts
- Dana Farber Cancer Institute - Boston
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2025-10 |
| Est. Completion | 2030-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06844383
The ClinicalTrials.gov registry entry for NCT06844383 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 121-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target. The listed sponsor is Prostate Cancer Clinical Trials Consortium, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 2 interventions - of which Talazoparib is the first listed.
NCT06844383 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06844383 about?
NCT06844383 is a clinical study titled "A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate". The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received ab...
What is the current status of trial NCT06844383?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 126 participants. The study started on 2025-10. Estimated completion is 2030-03.
What conditions does trial NCT06844383 study?
This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer).
What interventions are being tested in trial NCT06844383?
The interventions under investigation include: Talazoparib (DRUG), Talazoparib with enzalutamide (DRUG).
Who is sponsoring clinical trial NCT06844383?
This trial is sponsored by Prostate Cancer Clinical Trials Consortium, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06844383 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Adenocarcinoma)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
-
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
RECRUITING · Phase 2
-
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
RECRUITING · Phase 2
-
Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)
ACTIVE NOT RECRUITING · Phase 2
-
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Prostate Cancer (Adenocarcinoma)
All registered trials for this condition
mCRPC (Metastatic Castration-resistant Prostate Cancer)
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.